Your session is about to expire
← Back to Search
Monoclonal Antibodies
Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1
Waitlist Available
Led By Sameem Abedin, MD
Research Sponsored by Medical College of Wisconsin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group
Summary
This is a prospective, single-center phase 1 clinical study aimed at determining the maximum-tolerated dose and safety of the combination of gemtuzumab ozogamicin (GO) and pracinostat (P) in patients with relapsed/refractory acute myeloid leukemia.
Eligible Conditions
- Adult Acute Myeloid Leukemia
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
The number of subjects experiencing a dose-limiting toxicity.
Secondary study objectives
Number of subjects progression free at 6 months.
Number of subjects surviving at six months.
The number of subjects with a complete response.
+3 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
4Treatment groups
Experimental Treatment
Group I: Pracinostat with Gemtuzumab Ozogamicin MaintenanceExperimental Treatment2 Interventions
Response will be assessed through bone marrow biopsy on Day 28. Patients achieving at least a partial remission marrow will be offered up to 5 cycles of maintenance therapy. Maintenance should begin no later than 42 days after initial induction.
* Gemtuzumab Ozogamicin Maintenance: 2 mg/m\^2 intravenous administration on day 1, in a 28-day cycle.
* Pracinostat Maintenance: (In addition to GO, only if induction dose escalation occurs) 45 mg orally 3 days a week with 48 hours between dosing, for three consecutive weeks, followed by 1 week of rest, in a 28-day cycle.
Group II: Pracinostat 60 mg with Gemtuzumab OzogamicinExperimental Treatment2 Interventions
* Gemtuzumab Ozogamicin Induction: GO 3 mg/m\^2 on Day 1, 4, and 7
* Pracinostat: 60 mg administered orally 3 days a week with 48 hours between dosing for 3 consecutive weeks, followed by 1 week of rest, in 28-day cycles.
We will utilize a 3+3 design to determine the safe dose of pracinostat in combination with fixed dose GO. If there are no DLTs in the first three patients, the dose of pracinostat will be escalated to 60mg. Escalation to the next dose level will be done only after the third patient on the previous dose level has been observed for 28 days, and no DLTs were noticed. If there is 1 DLT, an additional 3 patients will be tested at same dose level. If there are ≥ 2 DLTs in 3 or 6 patients, the study will be placed on hold. If there is \< 2 DLTs in the first 3 or 6 patients, the dose of pracinostat will be escalated to 60mg. If there are no DLTs in the first 3 patients at 60 mg, an additional 3 patients will be enrolled to ensure 6 patients are treated at the MTD.
Group III: Pracinostat 45 mg with Gemtuzumab OzogamicinExperimental Treatment2 Interventions
* Gemtuzumab Ozogamicin Induction: GO 3 mg/m\^2 on Day 1, 4, and 7
* Pracinostat Induction: 45 mg administered orally 3 days a week with 48 hours between dosing for 3 consecutive weeks, followed by 1 week of rest, in 28-day cycles. We will utilize a 3+3 design to determine the safe dose of pracinostat in combination with fixed dose GO. If there are no DLTs in the first three patients, the dose of pracinostat will be escalated to 60mg. Escalation to the next dose level will be done only after the third patient on the previous dose level has been observed for 28 days, and no DLTs were noticed. If there is 1 DLT, an additional 3 patients will be tested at same dose level. If there are ≥ 2 DLTs in 3 or 6 patients, the study will be placed on hold. If there is \< 2 DLTs in the first 3 or 6 patients, the dose of pracinostat will be escalated to 60mg. If there are no DLTs in the first 3 patients at 60 mg, an additional 3 patients will be enrolled to ensure 6 patients are treated at the MTD.
Group IV: Gemtuzumab Ozogamicin Monotherapy MaintenanceExperimental Treatment1 Intervention
Response will be assessed through bone marrow biopsy on Day 28. Patients achieving at least a partial remission marrow will be offered up to 5 cycles of maintenance therapy. Maintenance should begin no later than 42 days after initial induction.
\*\*Gemtuzumab Ozogamicin Maintenance: 2 mg/m\^2 intravenous administration on day 1, in a 28-day cycle.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pracinostat - 45 mg
2019
Completed Phase 1
~20
Pracinostat - 60 mg
2019
Completed Phase 1
~20
Gemtuzumab Ozogamicin 2 mg/m^2
2019
Completed Phase 1
~20
Gemtuzumab Ozogamicin 3 mg/m^2
2019
Completed Phase 1
~20
Find a Location
Who is running the clinical trial?
Medical College of WisconsinLead Sponsor
635 Previous Clinical Trials
1,181,688 Total Patients Enrolled
Sameem Abedin, MDPrincipal InvestigatorMedical College of Wisconsin
4 Previous Clinical Trials
10,094 Total Patients Enrolled